BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $40.23 Average PT from Analysts
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average […]
More Stories
Contrasting Soluna (NASDAQ:SLNH) & MGT Capital Investments (OTCMKTS:MGTI)
Earnings and Valuation This table compares Soluna and MGT Capital Investments”s gross revenue, earnings per share and valuation. Gross Revenue...
Analyzing Mediaset España Comunicación (OTCMKTS:GETVY) and Vestas Wind Systems A/S (OTCMKTS:VWDRY)
Mediaset España Comunicación (OTCMKTS:GETVY – Get Free Report) and Vestas Wind Systems A/S (OTCMKTS:VWDRY – Get Free Report) are both...
Viant Technology Inc. (NASDAQ:DSP) Receives Average Recommendation of “Buy” from Brokerages
Shares of Viant Technology Inc. (NASDAQ:DSP – Get Free Report) have been assigned a consensus recommendation of “Buy” from the...
Bank of Hawaii Co. (NYSE:BOH) Given Average Rating of “Reduce” by Brokerages
Bank of Hawaii Co. (NYSE:BOH – Get Free Report) has received a consensus recommendation of “Reduce” from the six ratings...
Reviewing Summit Midstream (SMC) and The Competition
Volatility & Risk Summit Midstream has a beta of 2.37, indicating that its stock price is 137% more volatile than...
Financial Survey: WaveDancer (NASDAQ:WAVD) & PTC (NASDAQ:PTC)
WaveDancer (NASDAQ:WAVD – Get Free Report) and PTC (NASDAQ:PTC – Get Free Report) are both computer and technology companies, but...